Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€11.05

€11.05

0.940%
0.102
0.940%
-
 
28.03.24 / Tradegate WKN: A2QAME / Symbol: VTRS / Name: Viatris / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Viatris Inc. Stock

The Viatris Inc. stock is trending slightly upwards today, with an increase of €0.10 (0.940%) compared to yesterday's price.
So far the community has only identified positive things for Viatris Inc. stock. The most positive votes were given for criterium "Business model".

Pros and Cons of Viatris Inc. in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Viatris Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Viatris Inc. 0.940% -0.331% -10.907% 23.737% 11.239% -11.082% -56.952%
Indivior plc 1.000% 4.210% -1.232% 25.344% 45.080% 177.893% 253.616%
Opko Health Inc. 10.430% 22.561% 4.494% -17.774% -30.007% -73.656% -54.457%
Catalent Inc. 0.380% 1.758% -2.980% -16.680% 26.456% -40.115% 44.321%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon first evaluation of Viatris (VTRS) - a pharmaceutical company, the financials reveal a fascinating yet complex picture. While the organization has faced challenges in the past, it seems to have maintained a solid foundation with a mix of ups and downs that demand further exploration.

Stable Total Assets: VTRS boasts a significant total asset base, amounting to $50.02 billion in 2022. Although there has been a slight decline in total assets from $61.55 billion in 2020, it remains a positive aspect for the company.

Reduction in Total Liabilities: The company has managed to reduce its total liabilities from $38.59 billion in 2020 to $28.94 billion in 2022. This decrease in liabilities indicates improved financial health and a reduced debt burden for the company.

Comments

Sell Viatris Inc.
Show more

Buy Mylan NV
Show more

Buy Mylan NV
Show more

News

Is Viatris a Great Dividend Stock or Just a Value Trap?: https://g.foolcdn.com/editorial/images/768795/a-couple-reviewing-a-document-at-home.jpg
Is Viatris a Great Dividend Stock or Just a Value Trap?

Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?: https://g.foolcdn.com/editorial/images/752405/scientist-looks-at-test-tube.jpg
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?

As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent

Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/749955/investor-considers-laptop-with-notebook.jpg
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment